{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Idelalisib", "query": { "intervention": "Idelalisib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 51, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Idelalisib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T12:05:37.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02457598", "title": "Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Malignancies" ], "interventions": [ { "name": "Tirabrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Entospletinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2015-06-16", "completion_date": "2024-09-25", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Goshen, Indiana • Portland, Oregon", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02457598" }, { "nct_id": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2010-03-25", "completion_date": "2015-04-28", "has_results": true, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088048" }, { "nct_id": "NCT02993536", "title": "Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993536" }, { "nct_id": "NCT02136511", "title": "Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-10-28", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 4, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02136511" }, { "nct_id": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "20 mg/kg TRU-016 + Rituximab", "type": "BIOLOGICAL" }, { "name": "10 mg/kg TRU-016 + Rituximab", "type": "BIOLOGICAL" }, { "name": "TRU-016 20 mg/kg + Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "TRU-016 6-20 mg/kg + idelalisib + rituximab", "type": "BIOLOGICAL" }, { "name": "TRU-016 10-20 mg/kg + ibrutinib", "type": "BIOLOGICAL" }, { "name": "TRU-016 10-20 mg/kg + bendamustine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aptevo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2012-09", "completion_date": "2021-04-21", "has_results": false, "last_update_posted_date": "2021-05-20", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 8, "location_summary": "Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644253" }, { "nct_id": "NCT02468557", "title": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Previously Untreated Pancreatic Ductal Adenocarcinoma", "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-07-30", "completion_date": "2016-04-27", "has_results": true, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02468557" }, { "nct_id": "NCT02436135", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-06-05", "completion_date": "2017-11-20", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 2, "location_summary": "Stanford, California • Ann Arbor, Michigan", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02436135" }, { "nct_id": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Refractory Splenic Marginal Zone Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Richter Syndrome", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-02-19", "completion_date": "2022-01-04", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332980" }, { "nct_id": "NCT02439138", "title": "Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "GS-1101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-10", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439138" }, { "nct_id": "NCT07218341", "title": "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-03-09", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-03T12:05:37.956Z", "location_count": 9, "location_summary": "Mobile, Alabama • Tucson, Arizona • Jacksonville, Florida + 6 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Coon Rapids", "state": "Minnesota" }, { "city": "Ithaca", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218341" } ] }